Fluorescein 10% · injectable solution
Diagnostic Dye, Injections & Implants
Approved uses
Fluorescein angiography or angioscopy of the retina and iris vasculature
Adults 500 mg intravenously; children 7.7 mg/kg (35 mg per 10 pounds) up to a maximum of 500 mg, injected at about 1 mL per second into the antecubital vein
OFF-LABELNot in the FDA label for this product
Oral fluorescein angiography when intravenous access is refused or not tolerated
Sodium fluorescein 25 mg/kg mixed in 20 mL of water and swallowed in a single gulp in the largest pediatric comparison, which cites 20 to 30 mg/kg as the reported range
Comparative series · n=40
Comparative case series of 40 children aged 3 to 16 who underwent both routes within one week. All 40 completed the oral study against 24 of 40 for the intravenous study (100% versus 60%, P<0.0001), and among preschoolers 19 of 19 against 7 of 19 (P<0.0001); the 16 intravenous failures were needle fear in 14 and a positive fluorescein skin test in 2. Graded image quality was similar for foveal avascular zone visualization (P=0.8972), for clinically important findings (P>0.9999), and overall (P=0.2500). Median time to dye entry was 5.2 minutes and to the optimal angiogram 10.5 minutes. No adverse event occurred in either arm, but the authors state their sample was too small to evaluate the safety of the oral route.
Contraindications
Known hypersensitivity to fluorescein or any other ingredient in the product.
Injection 500 mg/5 mL (100 mg/mL), single-dose 5 mL glass vial
Excited by light between 465 and 490 nm, the dye fluoresces yellowish green at 520 to 530 nm. After rapid intravenous injection the unbound fraction circulating through the ocular vasculature is excited by the fundus camera flash, demarcating the retinal and choroidal vessels against adjacent structures.
Warnings & Precautions
- Anaphylaxis and death: Rare deaths due to anaphylaxis have been reported, and intolerance reactions are always unpredictable, but they are more frequent in patients who have previously had an adverse reaction after an injection with symptoms other than nausea and vomiting, and in patients with a history of allergy such as food or drug induced urticaria, asthma, eczema, or allergic rhinitis, so question each patient in detail before angiography.
- Respiratory reactions: Monitor closely in patients with a history of allergy or bronchial asthma, and keep an emergency tray available; an intradermal skin test of 0.05 mL read at 30 to 60 minutes may be performed when allergy is suspected, but a negative skin test is not proof that a patient is not allergic.
- Severe local tissue damage: Avoid extravasation during injection, because the high pH of the solution can result in severe local tissue damage; reported complications include severe pain in the arm for several hours, sloughing of the skin, superficial phlebitis, subcutaneous granuloma, and toxic neuritis along the median curve in the antecubital area. Stop the injection and treat the tissue and pain conservatively if significant extravasation occurs.
- Gastrointestinal distress: Nausea and/or vomiting and gastrointestinal distress occur commonly within the first few minutes following injection and usually subside within 10 minutes; diarrhea has also been reported.
- Incompatibility: Do not mix or dilute with other solutions or drugs, and flush the intravenous line before and after other drugs to avoid physical incompatibility reactions.
- Storage: Store at 2 to 25 degrees C and do not freeze.
Common Side Effects
The most common reaction is a temporary yellowish discoloration of the skin and urine, and urine may attain a bright yellow color; skin discoloration usually fades in 6 to 12 hours and urine discoloration in 24 to 36 hours. Nausea, vomiting, and gastrointestinal distress are common within the first few minutes and usually subside within 10 minutes; a strong taste may develop and diarrhea has been reported. Generalized hives and itching, bronchospasm, and anaphylaxis have been reported, with rare deaths. Cardiac arrest, basilar artery ischemia, severe shock, and death may occur rarely. Headache may occur, and convulsions and syncope may rarely occur following injection. Thrombophlebitis at the injection site has been reported, and extravasation causes intense local pain and a dull aching pain in the injected arm.
Pregnancy: Insufficient data in pregnant women to inform a drug-associated risk, and adequate animal reproduction studies have not been conducted; a single intravenous dose in pregnant rats distributed rapidly into the amniotic fluid and fetus. Give to a pregnant woman only if clearly needed.
Lactation: Demonstrated to transfer into human milk for up to 4 days after intravenous administration, and the label advises caution in a nursing woman.
Pediatric patients were included in clinical studies, with no overall difference in safety or effectiveness from adults.